Increased 1,5-anhydroglucitol predicts glycemic remission in patients with newly diagnosed type 2 diabetes treated with short-term intensive insulin therapy

Diabetes Technology and Therapeutics

Volumn 14, Issue 9, 2012, Pages 756-761

  Liu, Liehua ^a   Wan, Xuesi ^a   Liu, Juan ^a   Huang, Zhimin ^a   Cao, Xiaopei ^a   Li, Yanbing ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1,5 ANHYDROSORBITOL; FRUCTOSAMINE; GLUCOSE; HEMOGLOBIN A1C; INSULIN ASPART;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CARBOHYDRATE ANALYSIS; CONTINUOUS INFUSION; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN PUMP; INSULIN TREATMENT; INTRAVENOUS GLUCOSE TOLERANCE TEST; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT MONITORING; PRIORITY JOURNAL; REFERENCE VALUE; REMISSION; SENSITIVITY AND SPECIFICITY; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DEOXYGLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; FRUCTOSAMINE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; TIME FACTORS;

EID: 84865739499     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2012.0055     Document Type: Article

References (24)

1. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng J: Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004;27:2597-2602.
2. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H: Effect of intensive insulin therapy on beta-cell function and glycemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008;371:1753-1760.
3. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E: Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997;20:1353-1356.
4. Stickle D, Turk J: A kinetic mass balance model for 1, 5-anhydroglucitol: applications to monitoring of glycemic control. Am J Physiol 1997;273:E821-E830.
5. Yamanouchi T, Tachibana Y, Akanuma H, Minoda S, Shinohara T, Moromizato H, Miyashita H, Akaoka I: Origin and disposal of 1, 5-anhydroglucitol, a major polyol in the human body. Am J Physiol 1992;263:E268-E273.
6. Fluss R, Faraggi D, Reiser B: Estimation of the Youden Index and its associated cutoff point. Biom J 2005:47:458-472.
7. McGill JB, Cole TG, Nowatzke W, Houghton S, Ammirati EB, Gautille T, Sarno MJ: Circulating 1, 5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U. S. trial of the GlycoMark assay. Diabetes Care 2004;27:1859-1865.
8. Yamanouchi T, Ogata N, Tagaya T, Kawasaki T, Sekino N, Funato H, Akaoka L, Miyashita H: Clinical usefulness of serum 1, 5-anhydroglucitol in monitoring glycemic control. Lancet 1996;347:1514-1518.
9. Wajchenberg BL: Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218.
10. Godsland IF, Jeffs JA, Johnston DG: Loss of beta cell function as fasting glucose increases in the non-diabetic range. Diabetologia 2004;47:1157-1166.
11. Kohnert KD, Augstein P, Zander E, Heinke P, Peterson K, Freyse EJ, Hovorka R, Salzsieder E: Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 2009;32:1058-1062.
12. Won JC, Park CY, Park HS, Kim JH, Choi ES, Rhee EJ, Lee WY, Oh KW, Kim SW, Park SW: 1, 5-Anhydroglucitol reflects postprandial hyperglycemia and a decreased insulinogenic index, even in subjects with prediabetes and well-controlled type 2 diabetes. Diabetes Res Clin Pract 2009;84:51-57.
13. Yamanouchi T, Moromizato H, Shinohara T, Minoda S, Miyashita H, Akaoka I: Estimation of plasma glucose fluctuation with a combination test of hemoglobin A1c and 1, 5-anhydroglucitol. Metabolism 1992;41:862-867.
14. Dungan KM, Buse JB, Largay J, Kelly MM, Button EA, Kato S, Wittlin S: 1, 5-Anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 2006;29:1214-1219.
15. Yamanouchi T, Inoue T, Ogata E, Kashiwabara A, Ogata N, Sekino N, Yoshimura T, Ichiyanagi K, Kawasaki T: Post-load glucose measurements in oral glucose tolerance tests correlate well with 1, 5-anhydroglucitol, an indicator of overall glycemic state, in subjects with impaired glucose tolerance. Clin Sci 2001;101:227-233.
16. Stettler C, Stahl M, Allemann S, Diem P, Schmidlin K, Zwahlen M, Riesen W, Keller U, Christ E: Association of 1, 5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care 2008;31:1534-1535.
17. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681-1687.
18. Donath MY, Ehses JA, Maedler K, Schumann DM, Ellingsgaard H, Eppler E, Reinecke M: Mechanisms of beta-cell death in type 2 diabetes. Diabetes 2005;54(Suppl 2):S108-S113.
19. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H Glucose toxicity in beta-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 2003;52:581-587.
20. Meng X, Tancharoen S, Kawahara KI, Nawa Y, Taniguchi S, Hashiguchi T, Maruyama I: 1, 5-Anhydroglucitol attenuates cytokine release and protects mice with type 2 diabetes from inflammatory reactions. Int J Immunopathol Pharmacol 2010;23:105-119.
21. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY: Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517-1526.
22. Hu Y, Li L, Xu Y, Yu T, Tong G, Huang H, Bi Y, Weng J, Zhu D: Short-term intensive therapy in newly diagnosed type 2 diabetes partially restores both insulin sensitivity and betacell function in subjects with long-term remission. Diabetes Care 2011;34:1848-1853.
23. Xu W, Li YB, Deng WP, Hao YT, Weng JP: Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: a long-term follow-up study. Chin Med J (Engl) 2009;122:2554-2559.
24. Yamanouchi T, Minoda S, Yabuuchi M, Akanuma Y, Akanuma H, Miyashita H, Akaoka I: Plasma 1, 5-anhydro-dglucitol as new clinical marker of glycemic control in NIDDM patients. Diabetes 1989;38:723-729.